Pulmonary hypertension: From molecular pathophysiology to haemodynamic abnormalities

被引:5
|
作者
Duong-Quy, S. [1 ]
Riviere, S. [1 ]
Bei, Y. [1 ]
Duong-Ngo, C. [1 ]
Le-Dong, N. N. [1 ]
Hua-Huy, T. [1 ]
Dinh-Xuan, A. T. [1 ]
机构
[1] Univ Paris 05, Serv Physiol, Hop Cochin, UPRES EA 2511,Fac Med, F-75104 Paris, France
关键词
Pulmonary hypertension; Pulmonary arterial hypertension; Physiopathology; Haemodynamic; Molecular pathology; VASOACTIVE-INTESTINAL-PEPTIDE; RHO-KINASE INHIBITOR; SMOOTH-MUSCLE-CELLS; 5-HYDROXYTRYPTAMINE TRANSPORTER GENE; SERINE ELASTASE INHIBITOR; CONGENITAL HEART-DISEASE; NITRIC-OXIDE SYNTHASE; ARTERIAL-HYPERTENSION; TENASCIN-C; TRANSGENIC MICE;
D O I
10.1016/j.rmr.2012.03.009
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Pulmonary hypertension (PH) is a complex disorder resulting from many etiologies that cause disturbances of normal pulmonary haemodynamics. Recent breakthroughs have led to a better understanding of the pathophysiology of the disease. In PH, haemodynamic disturbances are closely linked to structural changes and excessive remodeling of pulmonary vessels, leading to progressive narrowing of the pulmonary vascular lumen. Imbalances between pulmonary vasoconstrictors and vasodilators on the one hand, and factors favoring cell proliferation and apoptosis on the other hand, probably account for most cases of PH. This review aims to update readers with the current knowledge on the molecular physiopathology of PH and how this can progress the therapeutic of this disorder. (C) 2012 SPLF. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:956 / 970
页数:15
相关论文
共 50 条
  • [1] The Role of Sex in the Pathophysiology of Pulmonary Hypertension
    Docherty, Craig K.
    Harvey, Katie Yates
    Mair, Kirsty M.
    Griffin, Sinead
    Denver, Nina
    MacLean, Margaret R.
    SEX-SPECIFIC ANALYSIS OF CARDIOVASCULAR FUNCTION, 2018, 1065 : 511 - 528
  • [2] Molecular mechanisms of pulmonary hypertension
    Yidiz, Pinar
    CLINICA CHIMICA ACTA, 2009, 403 (1-2) : 9 - 16
  • [3] Pulmonary Hypertension in COPD: Pathophysiology and Therapeutic Targets
    Zakynthinos, E.
    Daniil, Z.
    Papanikolaou, J.
    Makris, D.
    CURRENT DRUG TARGETS, 2011, 12 (04) : 501 - 513
  • [4] Haemodynamic and neuroendocrine effects of tezosentan in chronic experimental pulmonary hypertension
    Lourenco, Andre P.
    Vasques-Novoa, Francisco
    Oliveira-Pinto, Jose
    Fontoura, Dulce
    Roncon-Albuquerque, Roberto, Jr.
    Leite-Moreira, Adelino F.
    INTENSIVE CARE MEDICINE, 2012, 38 (06) : 1050 - 1060
  • [5] Haemodynamic evaluation of pulmonary hypertension
    Chemla, D
    Castelain, V
    Hervé, P
    Lecarpentier, Y
    Brimioulle, S
    EUROPEAN RESPIRATORY JOURNAL, 2002, 20 (05) : 1314 - 1331
  • [6] Cellular and Molecular Basis of Pulmonary Arterial Hypertension
    Morrell, Nicholas W.
    Adnot, Serge
    Archer, Stephen L.
    Dupuis, Jocelyn
    Jones, Peter Lloyd
    MacLean, Margaret R.
    McMurtry, Ivan F.
    Stenmark, Kurt R.
    Thistlethwaite, Patricia A.
    Weissmann, Norbert
    Yuan, Jason X. -J.
    Weir, E. Kenneth
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (01) : S20 - S31
  • [7] Pathophysiology and new advances in pulmonary hypertension
    Bousseau, Simon
    Fais, Rafael Sobrano
    Gu, Sue
    Frump, Andrea
    Lahm, Tim
    BMJ MEDICINE, 2023, 2 (01):
  • [8] Pathophysiology of pulmonary hypertension: Progresses and expectancies
    Montani, D.
    Guignabert, C.
    Perros, F.
    Humbert, M.
    REVUE DES MALADIES RESPIRATOIRES, 2012, 29 (08) : 950 - 952
  • [9] Pulmonary hypertension: Pathophysiology beyond the lung
    Oliveira, Aline C.
    Richards, Elaine M.
    Raizada, Mohan K.
    PHARMACOLOGICAL RESEARCH, 2020, 151
  • [10] Pathophysiology of right ventricular failure in pulmonary hypertension
    Bronicki, Ronald A.
    Baden, Harris P.
    PEDIATRIC CRITICAL CARE MEDICINE, 2010, 11 : S15 - S22